©Author(s) (or their employer(s)) 2026.
World J Crit Care Med. Mar 9, 2026; 15(1): 113310
Published online Mar 9, 2026. doi: 10.5492/wjccm.v15.i1.113310
Published online Mar 9, 2026. doi: 10.5492/wjccm.v15.i1.113310
Table 1 Cost-effectiveness of ventilatory strategies in the intensive care unit
| Strategy | Clinical context | Reported cost-effectiveness | Interpretation |
| NIV | Acute respiratory failure (COPD, cardiogenic pulmonary edema) | Reduces intubation, LOS and costs vs invasive ventilation; favorable ICER | Cost-effective when applied early in selected populations |
| HFNC | Hypoxemic respiratory failure | 2000-3000 pounds per QALY | Highly cost-effective, especially as alternative to intubation |
| Protective ventilation (LTVV) | ARDS/ALI | 13031 dollars per QALY vs conventional ventilation | Strong evidence of clinical and economic benefit |
| Prolonged mechanical ventilation | Patients requiring > 21 days of MV | 36000-44000 dollars per QALY (Taiwan); often > 100000 dollars in elderly | Low cost-effectiveness; high resource burden |
| ECMO | Severe ARDS | 43040 dollars per QALY (lifetime model) | Cost-effective in highly selected severe ARDS cases |
| Invasive ventilation in severe stroke | Patients ≥ 40 years old | Up to 266470 dollars per QALY | Poor cost-effectiveness; highlights limit of aggressive care |
| ICU admission vs ward care (severe sepsis) | Severe sepsis | 3338 dollars per QALY in younger patients; higher in elderly | Very cost-effective, though benefit declines with advanced age |
| ICU admission vs ward care (pneumonia, sepsis, ARDS) | Severe acute illness | Variable; ICU increases survival but at higher cost | Reinforces need for population-based thresholds in critical care |
| ARDS rescue therapies (prone positioning, inhaled nitric oxide, ECMO) | Refractory hypoxemia | Prone positioning < 10000 dollars/QALY; nitric oxide not cost-effective | Low-cost, evidence-based interventions maximize value |
- Citation: Barbosa OA. Ventilatory strategies in intensive care: Balancing clinical outcomes and cost-effectiveness. World J Crit Care Med 2026; 15(1): 113310
- URL: https://www.wjgnet.com/2220-3141/full/v15/i1/113310.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v15.i1.113310
